Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors
-
Clinical Trial Information
Trial Contact: Parker, Melanie; Frankos, Marie; Torrescano, Tanner; Armatti, Julie M; Jones, Jamie; Singh, Sarah H
Trial Phone: 321-843-1036 ; 321-842-8738 ; 321-841-8271 ; 321-843-5284 ; 3218412008 ; 321.841.7561
-
IRB No: 24.160.10
Protocol Abbrev: BCC021
Principal Investigator: Jaime C Gonzalez, MD
Phase: Drug: Phase I
Age Group: Pediatric; Adult
Secondary Protocol No: BCC021
Treatment: Drug: Silmitasertib, Drug: Irinotecan, Drug: Temozolomide, Drug: Vincristine
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT06541262
-
Objective
to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors
-
Key Eligibility
Age: Less than 30 years old at initial diagnosis
Pathology All subjects must have a confirmed diagnosis of tumor type. Phase I: Relapsed/refractory solid tumors: Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
Phase II:
Relapsed/refractory Neuroblastoma
Relapsed/refractory Ewing sarcoma
